Aptorum Therapeutics Granted U.S. Patent #12023334: Composition Including Rilpivirine And Method For Treating Tumors Or Cancer
Portfolio Pulse from Benzinga Newsdesk
Aptorum Therapeutics has been granted U.S. Patent #12023334 for a composition including Rilpivirine and a method for treating tumors or cancer.
July 02, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptorum Therapeutics has received a U.S. patent for a composition including Rilpivirine and a method for treating tumors or cancer. This patent could enhance the company's product portfolio and potentially lead to new treatment options.
The granting of a U.S. patent is a significant milestone for Aptorum Therapeutics, as it strengthens their intellectual property portfolio and could lead to new treatment options in the oncology space. This development is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100